- Home
- ABTS vs CANF Comparison
ABTS vs CANF Comparison
Compare ABTS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- CANF
- Stock Information
- Founded
- ABTS 2010
- CANF 1994
- Country
- ABTS Hong Kong
- CANF Israel
- Employees
- ABTS N/A
- CANF N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- CANF Health Care
- Exchange
- ABTS Nasdaq
- CANF Nasdaq
- Market Cap
- ABTS 9.8M
- CANF 13.5M
- IPO Year
- ABTS N/A
- CANF N/A
- Fundamental
- Price
- ABTS $4.35
- CANF $1.03
- Analyst Decision
- ABTS
- CANF Strong Buy
- Analyst Count
- ABTS 0
- CANF 2
- Target Price
- ABTS N/A
- CANF $14.00
- AVG Volume (30 Days)
- ABTS 52.6K
- CANF 145.3K
- Earning Date
- ABTS 08-16-2025
- CANF 08-29-2025
- Dividend Yield
- ABTS N/A
- CANF N/A
- EPS Growth
- ABTS N/A
- CANF N/A
- EPS
- ABTS N/A
- CANF N/A
- Revenue
- ABTS $6,711,225.00
- CANF $674,000.00
- Revenue This Year
- ABTS N/A
- CANF $461.72
- Revenue Next Year
- ABTS N/A
- CANF N/A
- P/E Ratio
- ABTS N/A
- CANF N/A
- Revenue Growth
- ABTS 299.11
- CANF N/A
- 52 Week Low
- ABTS $1.35
- CANF $0.98
- 52 Week High
- ABTS $14.10
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ABTS 55.49
- CANF 44.37
- Support Level
- ABTS $4.30
- CANF $1.00
- Resistance Level
- ABTS $5.39
- CANF $1.09
- Average True Range (ATR)
- ABTS 0.48
- CANF 0.03
- MACD
- ABTS 0.04
- CANF 0.00
- Stochastic Oscillator
- ABTS 61.37
- CANF 49.50
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).